HimishaBeltranMD

Genitourinary Oncology

Associate Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Overview of Dr. Beltran

Dr. Himisha Beltran is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, Dana-Farber Cancer Institute, and Brigham and Women's Hospital. She received her medical degree from New York Medical College and has been in practice 18 years. She is one of 457 doctors at Dana-Farber Cancer Institute and one of 379 doctors at Brigham and Women's Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021
Book by Phone+1(229) 702-0401

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004

Certifications & Licensure

MA State Medical License 2019 - 2025
NH State Medical License 2024 - 2024
NY State Medical License 2008 - 2019
PA State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study in Patients With Advanced Cancers Associated With Expression of DLL3 Start of enrollment: 2020 Dec 29
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
Michael C Haffner, Michael J Morris, Chien-Kuang C Ding, Erolcan Sayar, Rohit Mehra
Clinical Cancer Research. 2025-02-03
2 citations
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2025-02-01
Expression Patterns of DLL3 Across Neuroendocrine and Non-Neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.
John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey
Cancer Research Communications. 2025-01-28

Journal Articles

Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene Aberrations
Himisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open

Press Mentions

The Challenge of Finding New Tools to Fight Prostate CancerSeptember 9th, 2021
BET Inhibitors Show Promise in Overcoming Lineage Plasticity, a Newly Recognized Form of Resistance to Prostate Cancer DrugsJune 18th, 2021
Dana-Farber Cancer Institute, a Pioneer in Cancer Care and Research, Joins Caris' Precision Oncology AllianceFebruary 16th, 2021
Join now to see all